BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21320537)

  • 1. Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen.
    Franceschi V; Capocefalo A; Calvo-Pinilla E; Redaelli M; Mucignat-Caretta C; Mertens P; Ortego J; Donofrio G
    Vaccine; 2011 Apr; 29(16):3074-82. PubMed ID: 21320537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection.
    Calvo-Pinilla E; Rodríguez-Calvo T; Sevilla N; Ortego J
    Vaccine; 2009 Dec; 28(2):437-45. PubMed ID: 19857449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice.
    Marín-López A; Otero-Romero I; de la Poza F; Menaya-Vargas R; Calvo-Pinilla E; Benavente J; Martínez-Costas JM; Ortego J
    Antiviral Res; 2014 Oct; 110():42-51. PubMed ID: 25057758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An experimental subunit vaccine based on Bluetongue virus 4 VP2 protein fused to an antigen-presenting cells single chain antibody elicits cellular and humoral immune responses in cattle, guinea pigs and IFNAR(-/-) mice.
    Legisa DM; Perez Aguirreburualde MS; Gonzalez FN; Marin-Lopez A; Ruiz V; Wigdorovitz A; Martinez-Escribano JA; Ortego J; Dus Santos MJ
    Vaccine; 2015 May; 33(22):2614-9. PubMed ID: 25858859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(-/-) mice conferring protection against serotypes 1 and 4 of bluetongue virus.
    Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Benavente J; Brun A; Martínez-Costas JM; Ortego J
    Antiviral Res; 2017 Jun; 142():55-62. PubMed ID: 28322923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
    Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
    Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon α/β receptor knockout mice as a model to study bluetongue virus infection.
    Ortego J; de la Poza F; Marín-López A
    Virus Res; 2014 Mar; 182():35-42. PubMed ID: 24100234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunisation with bacterial expressed VP2 and VP5 of bluetongue virus (BTV) protect α/β interferon-receptor knock-out (IFNAR(-/-)) mice from homologous lethal challenge.
    Mohd Jaafar F; Belhouchet M; Vitour D; Adam M; Breard E; Zientara S; Mertens PP; Attoui H
    Vaccine; 2014 Jul; 32(32):4059-67. PubMed ID: 24886956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
    Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.
    Boone JD; Balasuriya UB; Karaca K; Audonnet JC; Yao J; He L; Nordgren R; Monaco F; Savini G; Gardner IA; Maclachlan NJ
    Vaccine; 2007 Jan; 25(4):672-8. PubMed ID: 17059856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant bluetongue virus with hemagglutinin epitopes in VP2 has potential as a labeled vaccine.
    Guo Y; Huang L; Bi K; Xu Q; Bu Z; Wang F; Sun E
    Vet Microbiol; 2020 Sep; 248():108825. PubMed ID: 32891953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus.
    Top S; Foucras G; Deplanche M; Rives G; Calvalido J; Comtet L; Bertagnoli S; Meyer G
    Vaccine; 2012 Feb; 30(9):1609-16. PubMed ID: 22244980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Swine adipose stromal cells loaded with recombinant bovine herpesvirus 4 virions expressing a foreign antigen induce potent humoral immune responses in pigs.
    Donofrio G; Taddei S; Franceschi V; Capocefalo A; Cavirani S; Martinelli N; Ottonello S; Ferrari M
    Vaccine; 2011 Jan; 29(5):867-72. PubMed ID: 21115049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
    Feenstra F; Pap JS; van Rijn PA
    Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge.
    Feenstra F; van Gennip RGP; Maris-Veldhuis M; Verheij E; van Rijn PA
    J Gen Virol; 2014 Sep; 95(Pt 9):2019-2029. PubMed ID: 24914064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep.
    Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H
    Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective Efficacy in Sheep of Adenovirus-Vectored Vaccines against Bluetongue Virus Is Associated with Specific T Cell Responses.
    Martín V; Pascual E; Avia M; Peña L; Valcárcel F; Sevilla N
    PLoS One; 2015; 10(11):e0143273. PubMed ID: 26619062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
    Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
    Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection.
    Kochinger S; Renevey N; Hofmann MA; Zimmer G
    Vet Res; 2014 Jun; 45(1):64. PubMed ID: 24928313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.
    Jabbar TK; Calvo-Pinilla E; Mateos F; Gubbins S; Bin-Tarif A; Bachanek-Bankowska K; Alpar O; Ortego J; Takamatsu HH; Mertens PP; Castillo-Olivares J
    PLoS One; 2013; 8(4):e60574. PubMed ID: 23593251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.